New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method

References (2)

1. Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation 2016;133:518-36. [Crossref] 2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373-498. [Crossref] 3. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106. [Crossref] 4. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015;66:677-88. [Crossref] 5. Wang TK, Sathananthan J, Marshall M, Kerr A, Hood C. Relationships between anticoagulation, risk scores and adverse outcomes in dialysis patients with atrial fibrillation. Heart Lung Circ 2016;25:243-9. [Crossref] 6. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014;11:1752-9. [Crossref] 7. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35. [Crossref] 8. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-82. [Crossref] 9. Sood MM, Rigatto C, Bueti J, Lang C, Miller L, Ponnam Palam A, et al. Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 2009;24:3162- 7. [Crossref] 10. Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK, et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 2015;129:197-201. [Crossref] 11. Pokorney SD. RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF). Presentation at the American Heart Association Annual Scientific Sessions (AHA 2019),
2. Philadelphia, PA, November 16, 2019. 12. Hu A, Niu J, Winkelmayer WC. Oral anticoagulation in p